MAPS Bulletin Autumn 1994 Vol. 05, No. 2 Building Towards Clinical Trials
The field of psychedelic research is at a critical turning point. Currently, basic physiological and psychological safety studies (Phase 1) are underway with MDMA, DMT, psilocybin and ibogaine. Within the next year, it may be possible to begin research into the therapeutic efficacy (Phase 2) of several of these psychedelic drugs as well as LSD and marijuana. Research on the horizon includes studies into the use of MDMA in the treatment of pain and distress in cancer patients, MDMA in the treatment of Post Traumatic Stress Disorder, ibogaine in the treatment of substance abusers, LSD in the treatment of substance abusers, psilocybin in the psychological treatment of AIDS and cancer patients, and marijuana in the treatment of the AIDS Wasting Syndrome.
While the field of psychedelic research looks exceptionally promising, support for free scientific inquiry must not be taken for granted. The challenge for researchers, and for MAPS, is to demonstrate as quickly as possible that this line of research carries benefits for the average American. Positive results from efficacy studies can do just that, if we have the regulatory approval, time and resources needed to conduct the research.
In the last several months, MAPS has increased its membership by over 100 people. If we can continue this rate of growth for the next year, MAPS will reach the point where it is of sufficient size to support its organizational expenses. In order to help MAPS grow and be more effective, we’d like to encourage you to renew your annual membership if it is time to do so, and to consider giving gift memberships to friends, family, or institutions. Special grants for research projects are also needed.
The field of psychedelic research made great progress in 1994, in part because of the partnership between MAPS members and staff and several excellent and devoted researchers. Thank you for your continued support and participation. Even more dramatic progress can take place in 1995.